Figure 3.

MoS₂/GO nanocomposites. (A) The overall schematic diagram depicting functionality and biocompatibility enhancement through the synthesizing of MoS₂/GO nanocomposites; (B) in vivo biodistribution of various materials in mice. The Mo contents were examined in mice 24 h post i.v. injection. The results from ICP-MS determination were shown as % of injected. In vivo imaging and lung accumulation analysis; (C) ICG fluorescent images of lungs from mice 24 h post-injection of free ICG and ICG-loaded nanomaterials; (D) quantification of relative ICG fluorescence in lungs (n = 3). ICG, indocyanine green. DOX loading capacity and tumor killing efficacy of different materials; (E) DOX loading capacity of nanomaterials (n = 4). * indicates p < 0.05 and # denotes p < 0.001, compared to bulk MoS₂-treated group; (F) in vitro tumor killing efficacy of DOX-loaded materials at the same mass concentrations (n = 5). The concentrations of materials were tailored for each type of cells as follows: 2 μg·mL⁻¹ for LLC cells, 6 μg·mL⁻¹ for B16 cells, 30 μg·mL⁻¹ for 4T1 cells, and 15 μg·mL⁻¹ for MDA-MB-231 cells; (G) representative images of metastatic tumor nodules in the lungs from treated and untreated mice with implantation of B16 murine melanoma cancer cells. DOX, doxorubicin; LLC, Lewis lung carcinoma. Reproduced with permission from ref. [89]. Copyright (2018). Springer Nature.